Shifting tides in the healthcare sector reveal that more and more patients are turning to health systems or IDNs for cancer care. This leads to a couple of questions: what does this mean for oncology and hematology practices, and how can pharma and life science companies effectively engage with healthcare providers (HCPs) from these notoriously […]

The efficacy and effectiveness of human papillomavirus (HPV) vaccination in preventing major oncogenic types of HPV (HPV infection, genital warts, and high-grade cervical lesions) has been well established. However, data to inform the relationship between quadrivalent HPV vaccination and the subsequent risk of invasive cervical cancer are lacking. To address this gap, Dr Jiayao Lei […]

Chimeric antigen receptor T-cell (CAR T) therapy has been proven effective for the treatment of several hematologic malignancies, including a recent approval for relapsed/refractory mantle cell lymphoma. Ongoing research of autologous CAR T-cell immunotherapy continues to change the landscape in the management of hematologic malignancies. Unfortunately, not all patients who might benefit from CAR T […]

Although the future of COVID-19 remains unknown, it is clear that the pandemic’s effects will linger in many aspects of cancer care and research, including oncology clinical trials. In a recent JAMA publication, Dr Daniel V. Araujo et al shared their perspectives on the evolving landscape of oncology research. Just as patient visits for treatments and […]